Is Off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications
Tóm tắt
Depressive disorders are a common form of psychiatric illness and cause significant disability. Regulation authorities, the medical profession and the public require high safety standards for antidepressants to protect vulnerable psychiatric patients. Ketamine is a dissociative anaesthetic and a derivative of a hallucinogen (phencyclidine). Its abuse is a major worldwide public health problem. Ketamine is a scheduled drug and its usage is restricted due to its abuse liability. Recent clinical trials have reported that ketamine use led to rapid antidepressant effects in patients suffering from treatment-resistant depression. However, various flaws in study designs, and possible biased reporting of results, may have influenced those findings. Further analyses of ketamine use are needed to ensure patient safety. The use of ketamine in research and treatment of depressive disorders is controversial. Recently, mental health professionals raised ethical concerns about an ongoing ketamine trial in the UK. Also, a Canadian agency reviewed the existing evidence and did not recommend prescribing ketamine to treat depressive disorders. Findings obtained from tightly controlled research settings cannot be easily translated to clinical practice as substance abuse is commonly comorbid with depressive disorders. An effective antidepressant should reduce severity of depressive symptoms without liability problems. Although the US FDA has not approved the use of ketamine to treat depressive disorders, some psychiatrists offer off-label repeat prescription of ketamine. Prescribing ketamine for treating depressive disorders requires substantial empirical evidence. Clinicians should also consider research findings on ketamine abuse. Depressive disorders can be chronic conditions and the current evidence does not rule out the risk of substance abuse after repeat prescription of ketamine. Off-label ketamine use in treating depressive disorders may breach ethical and moral standards, especially in countries seriously affected by ketamine abuse. This article presents two real-world clinical vignettes which highlight ethical principles and theories, including autonomy, nonmaleficience, fidelity and consequentialism, as related to off-label ketamine use. We urge clinicians to minimise the risk of harming patients by considering the empirical evidence on ketamine properties and attempting all standard antidepressant therapies before considering the off-label use of ketamine.
Tài liệu tham khảo
Ketamine Hydrochloride injection, JHP Pharmaceuticals LLC. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/016812s039lbl.pdf). Accessed 20 September 2015.
Trujillo KA, Smith ML, Sullivan B, Heller CY, Garcia C, Bates M. The neurobehavioral pharmacology of ketamine: implications for drug abuse, addiction, and psychiatric disorders. Lab Animal Res J. 2011;52(3):366–78.
Li JH, Vicknasingam B, Cheung YW, Zhou W, Nurhidayat AW, Jarlais DC, et al. To use or not to use: an update on licit and illicit ketamine use. Substance Abuse and Rehabilitation. 2011;16(2):11–20.
Henden E, Baeroe K. Providing free heroin to addicts participating in research – ethical concerns and the question of voluntariness. B J Psych Bulletin. 2015;39:28–31.
Ketamine, Drug Enforcement Administration. http://www.deadiversion.usdoj.gov/drug_chem_info/ketamine.pdf. Accessed 23 October 2014.
Network DAW. Emergency department trends from the Drug Abuse Warning Network: final estimates 1995–2002. Rockville MD: Department of Health and Human Services; 2013.
McCambridge J, Winstock A, Hunt N, Micheson L. 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. Eur Addict Res. 2007;13:57–64.
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archive of General Psychiatry. 1994;51(3):199–214.
Jansen KL, Darracot-Cankovic R. The nonmedical use of ketamine, part two: A review of problem use and dependence. J Psychoactive Drugs. 2001;33(2):151–8.
Dillon P, Copeland J, Jansen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend. 2003;69(1):23–8.
Central Narcotic Bureau (Singapore) http://www.cnb.gov.sg/drugs/bannedsubstance/ketamine.aspx. Accessed on 11 August 2015.
Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS, et al. Grand challenges in global mental health. Nature. 2011;475:27–30.
Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62:10–7.
Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369–88.
Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychpharmacol. 2014. [Epub ahead of print].
Zarate Jr CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939–46.
Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012;37(6):1526–33.
Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76(3):247–52.
Mathew SJ, Murrough JW. aan het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13(1):71–82.
Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250–6.
Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76(12):970–6.
Could ketamine become the next great depression drug? http://america.aljazeera.com/watch/shows/america-tonight/articles/2015/2/12/Ketamine.html. Accessed on 21 August 2015.
Randall SS. Regulating Off-label Drug Use- Rethinking the role of the FDA. N Engl J Med. 2008;358:14.
Aan Het Rot M, Collins K, Murrough J, Perez A, Reich D, Charney D, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;7:139–45.
Rasmussen KG. Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety. Progress in Neuropsychopharmacology. 2015;S0278–5846(15):00003–2.
Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67(2):247–57.
Ketamine-ECT Study (http://www.nets.nihr.ac.uk/_data/assets/pdf_file/0003/81705/PRO-10-90-04.pdf). Accessed on 21 August 2015.
ECT and ketamine in the treatment of depression - a response http://www.theguardian.com/science/head-quarters/2014/jun/30/electroconvulsive-therapy-ketamine-depression-treatment-ect. Accessed on 21 August 2015.
Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 2010;105(1):121–33.
Coppel DL, Dundee JW. Psychosis and ketamine. Br Med J. 1972;1(5803):805.
Read J, Bentall R, Bracken P, Danquah, Dillon J, Fernando S, et al. Open letter from nine mental health experts to funders and ethics committee about ketamine and electroshock therapy study. United Kingdom: 2014. https://johnreadblog.wordpress.com/2014/06/21/letter-from-nine-mental-health-expertsto-funders-and-ethics-committee-about-ketamine-electroshock-therapy-study/. Last accessed on 12th January 2016.
Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK. Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry. 2013;47(8):710–27.
Canadian Agency for Drugs and Technologies in Health. Intravenous Ketamine for the Treatment of Mental Health Disorders: A Review of Clinical Effectiveness and Guideline. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2014.
Murrough JW, Soleimani L, DeWilde KE, Collins KA, Lapidus KA, Iacoviello BM, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;12:1–10.
Diazgranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71(12):1605–11.
Zarate Jr CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–64.
Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, et al. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs. 2012;26(3):189–204.
Wise RA. Psychomotor stimulant properties of addictive drugs. Annals of New York Academy of Science. 1988;537:228–34.
Hirschfield RMA. The epidemiology of depression and the evolution of treatment. J Clin Psychiatry. 2012;73(1):5–9.
Barr AM, Markou A, Phillips AG. A ‘crash’ course on psychostimulant withdrawal as a model of depression. Trends in Pharmacological Science. 2002;23(10):475–82.
Schatzberg AF. A word to the wise about ketamine. Am J Psychiatr. 2014;171(3):262–4.
Sanacora G, Schatzberg AF. Ketamine: Promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology. 2015;40:259–67.
Lua AC, Lin HR, Tseng YT, Hu AR, Yeh PC. Profiles of urine samples from participants at rave party in Taiwan: prevalence of ketamine and MDMA abuse. Forensic Sci Int. 2003;136:47–51.
The American Psychiatric Association Task Force. Task Force Report 14: The electroconvulsive therapy. Washington: American Psychiatric Association; 1978.
Bandura A. Self-Efficacy: The Exercise of Control. W.H. Freeman 119: 343–9 as quoted in Henden E and Baeroe K. Providing free heroin to addicts participating in research – ethical concerns and the question of voluntariness. B J Psych Bulletin. 2015;39:28–31.
Salvadore G, Singh JB. Ketamine as a fast acting antidepressant: current knowledge and open questions. CNS Neurosci Ther. 2013;19(6):428–36.
Lo JN, Cumming JF. Interaction between sedative premedicants and ketamine in man in isolated perfused rat livers. Anesthesiology. 1975;43(3):307–12.
Zhang MW, Ho RC. Ketamine’s potential as a rapid antidepressant was overplayed. BMJ. 2015;351:h4467.
University of Oxford. First UK study of ketamine for people with severe depression. Press release, 3 April 2014. (http://www.ox.ac.uk/news/2014-04-03-first-uk-study-ketamine-peoplesevere-depression). Accessed on 11 August 2015.
Ketamine: The Future of Depression Treatment (http://www.webmd.com/depression/news/20140923/ketamine-depression). Accessed on 11 August 2015.
Rave drug holds promise for treating depression fast (http://www.nature.com/news/rave-drug-holds-promise-for-treating- depression-fast-1.16664). Accessed on 11 August 2015.